Colorectal Cancer Clinical Trials in Detroit

Showing 61-80 of 165 trials

ACTIVE_NOT_RECRUITINGPHASE1/PHASE2< 1 mile

A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies

NCT05039177

* To evaluate the safety and tolerability of escalating doses of ERAS-007 in combination with other cancer therapies in study participants with advanced GI malignancies. * To determine the Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD) of ERAS-007 administered in combination with other cancer therapies. * To evaluate the antitumor activity of ERAS-007 in combination with other cancer therapies. * To evaluate the PK profiles of ERAS-007 and other cancer therapies when administered in combination.

Metastatic Colorectal CancerMetastatic Pancreatic Ductal Adenocarcinoma

Erasca, Inc.102 participantsStarted Sep 2021

Birmingham, Alabama, United States • Duarte, California, United States • Orange, California, United States +11 more locations

APPROVED_FOR_MARKETING< 1 mile

Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal Cancer

NCT02286492

The objective of the program is to provide access to TAS-102 to patients with metastatic colorectal cancer who are refractory to or failing standard chemotherapy, are new to therapy with TAS-102 and in whom therapy with TAS-102 is clinically indicated.

Colorectal Cancer Metastatic

Taiho Oncology, Inc.

Birmingham, Alabama, United States • Scottsdale, Arizona, United States • Fresno, California, United States +30 more locations

A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies

Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal Cancer

Colorectal Cancer Trials in Other Cities

Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)

A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery

Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer

A Study of NBF-006 in Non-Small Cell Lung, Pancreatic, or Colorectal Cancer

Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation

MGD019 DART® Protein in Unresectable/Metastatic Cancer

Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer

Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (CRC)

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

Comparative Effectiveness of FITs With Colonoscopy

AN0025 and Pembrolizumab Combination in Advanced Solid Tumors

Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer

Development of a Cell Free DNA Assay as a Biomarker for Predicting Early Non-response to Therapy in Metastatic Cancer

Impact of a Patient-Centered Program for Low Anterior Resection Syndrome a Multicenter Randomized Controlled Trial

Other Conditions in Detroit